Selling a healthcare services business in the UK

You own a UK healthcare services business worth between £5M and £50M in enterprise value. Maybe a dental group of three to twelve sites. A veterinary practice or a specialist referral platform. A care home group with mixed private and Local Authority funding. A mental health provider with contracted NHS work. An occupational health business serving corporate clients. A specialist clinic in aesthetics, fertility or ophthalmology.

What unites our healthcare services clients is that the business is regulated, the clinical or care quality matters as much as the financial performance, and the buyer landscape is highly concentrated. Most owners we work with have been approached by at least one consolidator before they reach us. The reason they pick up the phone is not the existence of approaches — it is the suspicion that running a real process across the full buyer pool will produce a materially better outcome than working a single bid.

We typically engage 12 to 24 months before a target exit. That window gives time to address whatever needs addressing on regulatory standing, clinician retention, or financial reporting hygiene before the buyer diligence pack lands. Single-shareholder businesses, family ownership structures, and partner-led groups are all standard.

This is not the right fit if your business sits below £5M EV, or if the regulatory position is in active remediation rather than near completion. In both cases we would prefer to point you toward the right next step rather than run a process that does not serve you. It is also not the right fit if you have decided to accept a specific buyer's approach and simply want execution support — that is a different mandate, and a different fee profile.

Healthcare services buyers run a sharper, more regulated diligence than buyers in almost any other sector we work in. Six items consistently sit at the top of every diligence pack we have read across dental, vet, care, mental health and specialist clinics in the last two years.

CQC standing first. Outstanding or Good ratings materially affect both deal certainty and headline price. Requires Improvement or Inadequate ratings rarely kill deals, but they almost always discount them and frequently lengthen completion by months. If a remediable issue exists, we typically advise dealing with it six to twelve months ahead of any process, not during it.

Clinician retention second. Specialist clinicians — dentists, vets, psychiatrists, clinical psychologists, ophthalmologists — are scarce, and buyers know it. Tenure data, restrictive covenants, average billings per practitioner, and any post-sale lock-in arrangements all sit near the top of the pack. Sales where senior clinicians have not been engaged with the transaction story before going to market consistently re-trade or fall apart at completion.

Site economics third. Per-site EBITDA, occupancy or chair-time utilisation, case-load mix, and payer-mix breakdown by site. Multi-site groups where individual site performance varies widely against the group average are valued on the weaker sites, not the stronger. Cleaning up site-level reporting before going to market is high-return readiness work.

Payer mix fourth. The split between NHS / ICB-funded, Local Authority funded, insurer funded and private self-pay revenue tells the buyer how the business will fare across the regulatory and reimbursement cycle. Long-tenor contracted NHS work supports higher multiples because it is visible; pure self-pay can support a premium where the brand and clinical reputation are strong, but the revenue is less predictable.

Fifth and sixth: capex profile and property structure. Buyers want to see sustainable capex, not a year of deferred replacement that flatters reported EBITDA. They also want to understand whether sites are freehold or leasehold, and what the lease tail looks like. Headline EBITDA matters less than buyers willing to pay for the cash earnings net of all these. We help owners build the diligence pack that answers all six of these honestly and in advance — see exit planning for how that runs.

Our six-stage process runs senior-led from first conversation to completion. For healthcare services, three things shape how it plays out in practice.

First, regulated diligence sits on a longer clock than commercial diligence. CQC reports, contractual novation with NHS England or ICBs, and Local Authority notification all run on timelines we do not control. We build that into the process design rather than pretending it does not exist, which avoids the late-stage surprises that derail healthcare deals more often than any other diligence area.

Second, the buyer pool is concentrated. There are typically 8–15 active PE-backed consolidators across dental, vet, care, mental health and specialist clinics at any given time, each with distinct strategies on site size, geographic preference, payer mix and integration intensity. The CMA market investigation into the veterinary sector has also reshaped expected timelines for vet deals specifically. Knowing which consolidators are deploying capital today, and on what terms, is the difference between a process that generates real competition and one that ends with a single buyer dictating terms.

Third, clinician engagement matters. We work with owners to structure how and when key clinicians are told about the process. Get this wrong and you risk both the deal and the team. Get it right and you protect both. The detail of that engagement is something we build into the process design from the first conversation, not a problem we react to at completion.